SequelSEC

CERO THERAPEUTICS HOLDINGS, INC. CERO

Biological Products, (No Diagnostic Substances) · CIK 0001870404 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
Unavailable
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

CERO THERAPEUTICS HOLDINGS, INC. (CERO) reported net income of -$19.92M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from CERO THERAPEUTICS HOLDINGS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

CERO THERAPEUTICS HOLDINGS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312023-12-312022-12-31
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating incomeUnavailable-$7.68M-$2.91M
Net income-$19.92M-$7.29M-$667.74K
Research & developmentUnavailable$5.29MUnavailable
Weighted-average diluted sharesUnavailableUnavailableUnavailable
Pretax income-$19.92M-$2.44M-$68.58K
Income tax expenseUnavailable$94.82K$599.16K
Diluted EPSUnavailable$-1,248.64Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrativeUnavailable$2.39M$2.84M
Selling & marketingUnavailableUnavailableUnavailable

Balance

CERO THERAPEUTICS HOLDINGS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312023-12-312022-12-31
Cash & equivalentsUnavailable$96.87K$475.87K
Total assets$3.64M$5.13M$42.37M
Current assets$2.73M$1.97M$42.37M
Total liabilities$9.09M$5.08M$39.90M
Current liabilities$9.09M$3.51M$30.75M
Total equity incl. NCI-$5.45M-$42.06M-$11.00M
Temporary (mezzanine) equityUnavailable$8.44M$13.47M
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$7.58M$1.67MUnavailable

Cash flow

CERO THERAPEUTICS HOLDINGS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312023-12-312022-12-31
Operating cash flow-$16.10M-$1.52M-$1.09M
Capital expendituresUnavailableUnavailableUnavailable
Investing cash flowUnavailable-$7.94M$180.84M
Financing cash flowUnavailable-$32.58M-$138.70M
Net change in cashUnavailable-$42.04M$41.04M
Stock-based compensationUnavailableUnavailableUnavailable
Common dividends paid$127.14KUnavailableUnavailable
Common share repurchasesUnavailable$33.48M$139.35M
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

CERO THERAPEUTICS HOLDINGS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312023-12-312022-12-31
Free cash flowUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio0.30x0.56xUnavailable
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CERO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-19View SEC filing
10-Q · Filed 2025-08-22View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2023-12-31

Difference 33665033 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.